Hot on the TRAIL of graft vs. host disease

Public release date: 15-May-2013
[ | E-mail | Share ]

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation

For patients with leukemia and other hematological malignancies, transplantation of hematopoietic stem cells (HSCT) can be a powerfully effective therapy. In addition to the desirable anti-tumor effect, transplanted cells can also attack the host tissue, resulting in graft-versus-host disease (GVHD). In this issue of the Journal of Clinical Investigation, Arnab Ghosh and colleagues at Memorial Sloan-Kettering Cancer Center found that expression of a protein that causes cell death, TRAIL, in transplanted cells was critical for an effective anti-tumor response. Immune cells engineered to express higher levels of TRAIL killed the cells that cause GVHD and increased anti-tumor activity. In an accompanying commentary, Nelson Chao suggests that new therapeutics may take advantage of TRAIL-expressing cells to promote an anti-tumor response without putting patients at risk for GVHD.

###

TITLE: Fratricidal TRAIL+T cells suppress GVHD and augment anti-tumor activity after bone marrow transplantation

AUTHOR CONTACT:
Arnab Ghosh
Memorial Sloan-Kettering Cancer Center, New York, , USA
Phone: 646-888-2317; E-mail: ghosha1@mskcc.org

View this article at: http://www.jci.org/articles/view/66301?key=66e50de3cd0d7e99a4d8

ACCOMPANYING COMMENTARY

TITLE: Blazing a new TRAIL in hematopoietic cell transplantation

AUTHOR CONTACT:
Nelson J. Chao
Duke University Medical Center, Durham, NC, USA
Phone: 919-668-1011; Fax: 919-668-1091; E-mail: chao0002@mc.duke.edu

View this article at: http://www.jci.org/articles/view/69909?key=43f0101604c8f6bb12da

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 15-May-2013
[ | E-mail | Share ]

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation

For patients with leukemia and other hematological malignancies, transplantation of hematopoietic stem cells (HSCT) can be a powerfully effective therapy. In addition to the desirable anti-tumor effect, transplanted cells can also attack the host tissue, resulting in graft-versus-host disease (GVHD). In this issue of the Journal of Clinical Investigation, Arnab Ghosh and colleagues at Memorial Sloan-Kettering Cancer Center found that expression of a protein that causes cell death, TRAIL, in transplanted cells was critical for an effective anti-tumor response. Immune cells engineered to express higher levels of TRAIL killed the cells that cause GVHD and increased anti-tumor activity. In an accompanying commentary, Nelson Chao suggests that new therapeutics may take advantage of TRAIL-expressing cells to promote an anti-tumor response without putting patients at risk for GVHD.

###

TITLE: Fratricidal TRAIL+T cells suppress GVHD and augment anti-tumor activity after bone marrow transplantation

AUTHOR CONTACT:
Arnab Ghosh
Memorial Sloan-Kettering Cancer Center, New York, , USA
Phone: 646-888-2317; E-mail: ghosha1@mskcc.org

View this article at: http://www.jci.org/articles/view/66301?key=66e50de3cd0d7e99a4d8

ACCOMPANYING COMMENTARY

TITLE: Blazing a new TRAIL in hematopoietic cell transplantation

AUTHOR CONTACT:
Nelson J. Chao
Duke University Medical Center, Durham, NC, USA
Phone: 919-668-1011; Fax: 919-668-1091; E-mail: chao0002@mc.duke.edu

View this article at: http://www.jci.org/articles/view/69909?key=43f0101604c8f6bb12da

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2013-05/joci-hot050813.php

Robin Givens Gus Malzahn hyperemesis gravidarum BCS Bowls palestine powerball winner powerball winner